Clinical Trial Update: Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating long-acting phosphodiesterase-5 inhibitors as add-on therapy for patients with pulmonary arterial hypertension already treated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Snippet

Sponsor: Rabin Medical Center | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: UNKNOWN